⚕ GalenOps CRO console
← 709 (USA)

709-1102

completed
Study: Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. Phase II · Site: 709 (USA) (Dr. Novak) · consented 2013-01-15
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Mild APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-11 (study day 28.0); relationship: PROBABLE

moderate assessed 2026-08-18

Moderate APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-11 (study day 28.0); relationship: PROBABLE

mild assessed 2026-08-18

Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-11 (study day 28.0); relationship: PROBABLE

moderate assessed 2026-08-18

Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-11 (study day 28.0); relationship: PROBABLE

mild assessed 2026-08-18

Mild APPLICATION SITE VESICLES — outcome: RECOVERED/RESOLVED; onset 2013-03-26 (study day 71.0); relationship: PROBABLE

mild assessed 2026-08-18

Mild DIZZINESS — outcome: RECOVERED/RESOLVED; onset 2013-03-20 (study day 65.0); relationship: POSSIBLE

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.